General
Preferred name
FILOREXANT
Synonyms
MK-6096 ()
P&D ID
PD050337
CAS
1088991-73-4
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Drug indication
Insomnia
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Filorexant (MK-6096) is an orally bioavailable potent and selective reversible antagonist of OX1 and OX2 receptor(<3 nM in binding).
PRICE 102
DESCRIPTION Filorexant is a dual orexin receptor antagonist (DORA) . The compound was being developed by Merck Sharp & Dohme Corp. as a potential treatment for insomnia. (GtoPdb)
DESCRIPTION Filorexant, a selective reversible and orally bioavaliable antagonist of OX(1)R receptor and OX(2)R receptor, could probably be an effective compound in the treatment of insomnia. It is still under the Phase II trial by Merck. Binding Ki: less than 3 nM. (BOC Sciences Bioactive Compounds)
DESCRIPTION Filorexant (MK-6096) is an orally bioavailable, effective, and selective reversible antagonist of OX1 and OX2 receptors, with (Ki <3 nM). (TargetMol Bioactive Compound Library)
Compound Sets
16
BOC Sciences Bioactive Compounds
filorexant-cas-1088991-73-4-item-474337
Cayman Chemical Bioactives
29490
ChEMBL Drugs
CHEMBL2107822
Concise Guide to Pharmacology 2017/18
4460
Concise Guide to Pharmacology 2019/20
4460
Concise Guide to Pharmacology 2021/22
4460
Concise Guide to Pharmacology 2023/24
4460
Drug Repurposing Hub
DrugBank
DB12158
EU-OPENSCREEN Bioactive Compound Library
EOS101446
Guide to Pharmacology
4460
Mcule NIBR MoA Box Subset
MCULE-2170980351
MedChem Express Bioactive Compound Library
HY-15653
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
TargetMol Bioactive Compound Library
T16096
External IDs
25
Properties
(calculated by RDKit )
Molecular Weight
420.2
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
0
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
3
cLogP
4.31
TPSA
68.21
Fraction CSP3
0.33
Chiral centers
2.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
OX1
OX2
HCRTR1, HCRTR2
Orexin Receptor (OX Receptor)
Member status
member
MOA
Orexin 1 receptor antagonist, Orexin 2 receptor antagonist
orexin receptor antagonist
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Solubility
10 mM in DMSO
Source data